Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?

Lwin, May; Holroyd, Christopher; Wallis, Dinny; Davidson, Brian; Goulston, Lyndsey; de Graaf, Hans; Edwards, Christopher J

Lwin, May; Holroyd, Christopher; Wallis, Dinny; Davidson, Brian; Goulston, Lyndsey; de Graaf, Hans; Edwards, Christopher J.

Lwin M; NIHR Clinical Research Facility.
Holroyd C; Department of Rheumatology, University Hospital Southampton, Southampton, UK.
Wallis D; Department of Rheumatology, University Hospital Southampton, Southampton, UK.
Davidson B; Department of Rheumatology, University Hospital Southampton, Southampton, UK.
Goulston L; NIHR Clinical Research Facility.
de Graaf H; NIHR Clinical Research Facility.
Edwards CJ; NIHR Clinical Research Facility.

Rheumatol Adv Pract ; 4(2): rkaa061, 2020.

Article in English | MEDLINE | ID: covidwho-933892

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Rheumatol Adv Pract Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google